Navigation Links
Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institute's 2nd Annual Challenge of Antibacterial Development Conference
Date:4/22/2008

izes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community-acquired and hospital-acquired pathogens. The Company's integrated research strategy, which combines state of the art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the RX-1741 designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the RX-3341 program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin-resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these programs is focused on design and development of an orally active macrolide for community use for treatment of skin infections, including those caused by MRSA. The second discovery program is directed towards identifying a new chemical class of antibiotics active against multi-drug resistant Gram-negative bacteria.

For more information on the ribosome and the Rib-X mission, please visit the Company website at http://www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
3. Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections
4. Vion Pharmaceuticals Files Plan With Nasdaq
5. Amylin Pharmaceuticals to Webcast First Quarter Results
6. Paloma Pharmaceuticals to Present at the American Association for Cancer Research
7. Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
8. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
9. Pharmaceuticals & Biotechs to Share Insights for Developing Leaders in a Fast-Paced, Competitive Industry
10. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
11. Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled Bipolar Trans Carotenoid Salts and Their Uses, for Its Family of First-In-Class Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sep. 02, 2015 ... the addition of Jain PharmaBiotech,s new report ... to their offering. This report briefly ... sequencing technologies, and their applications. Current large and ... developing them. Various applications of sequencing are described ...
(Date:9/2/2015)... Research and Markets ( ... new report "Gene Therapy - Technologies, Markets and ... for gene therapy are difficult to estimate as there ... is marketed in China since ... 2014-2024. The estimates are based on epidemiology of diseases ...
(Date:9/2/2015)... CUMBERLAND, R.I. , Sept. 2, 2015 /PRNewswire/ ... has been enrolled in the multicenter Phase 2 ... for the long-term treatment of recurrent subfoveal choroidal ... AMD).  NT-503 is a unique vascular endothelial growth ... versatile ECT implant. "This landmark proof-of-concept ...
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... YORK, April 7, 2008 Medicsight PLC, a,subsidiary ... ), and an industry,leader in the development of ... in the early detection and diagnosis of,disease, announces ... the,world,s leading medical imaging and picture archiving and ...
... 2008 Ardea Biosciences,Inc. (Nasdaq: RDEA ) ... its,second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs),at the ... on two of the Company,s mitogen-activated ERK kinase,(MEK) ... the American,Association for Cancer Research (AACR) annual meeting., ...
... 2008 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ... Agreement with Open Monoclonal Technologies (OMT), a private,company ... Sangamo will,provide a non-exclusive, worldwide license to OMT ... Sangamo,s proprietary zinc finger,DNA-binding protein (ZFP) technology. OMT ...
Cached Biology Technology:Medicsight Announces New Marketing Partnership with INFINITT 2Medicsight Announces New Marketing Partnership with INFINITT 3Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 2Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences 3Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals 2Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals 3
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
(Date:8/11/2015)... August 11, 2015 Today, ZUK announced its ... as well as expected revenues in 2015 that relate to sales ... revenue guidance of approximately 2,200 MSEK for 2015. Jörgen ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Rep. Honda to Visit Crossmatch in Redwood City 2
... Shakespeare. In humans, nature may be less than half of ... researchers has found. In the first study of its ... explain why human birds of a feather flock together, but ... upon the social environment in which individuals interact with one ...
... Stanford University scientists have built the first solar cell made ... used in photovoltaic devices today. The results are ... ACS Nano . "Carbon has the potential to ... author Zhenan Bao, a professor of chemical engineering at Stanford. ...
... stem cells such as regenerating damaged tissues or organs ... past decade. While these types of applications are exciting, it ... immediate impact of stem cells on human health will most ... drugs. , The ability to generate stem cells by reprogramming ...
Cached Biology News:Social factors trump genetic forces in forging friendships, CU-led study finds 2Stanford scientists build the first all-carbon solar cell 2Stanford scientists build the first all-carbon solar cell 3The role of stem cells in developing new drugs 2
Cyan Standard is 7-hydroxy-4-trifluoromethylcoumarin...
Endothelin-converting enzyme 1 (EC 3.4.24.71) (ECE-1). [Source:Uniprot/SWISSPROT;Acc:P42892] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Red Standard is sodium salt of resorufin....
Oligodendrocyte Marker O1 MAb (Clone O1)...
Biology Products: